BRPI0515163A - métodos para tratar hemoptise ou sangramento traqueal, brÈnquico ou alveolar local - Google Patents

métodos para tratar hemoptise ou sangramento traqueal, brÈnquico ou alveolar local

Info

Publication number
BRPI0515163A
BRPI0515163A BRPI0515163-5A BRPI0515163A BRPI0515163A BR PI0515163 A BRPI0515163 A BR PI0515163A BR PI0515163 A BRPI0515163 A BR PI0515163A BR PI0515163 A BRPI0515163 A BR PI0515163A
Authority
BR
Brazil
Prior art keywords
methods
bronchial
alveolar
bleeding
local
Prior art date
Application number
BRPI0515163-5A
Other languages
English (en)
Inventor
Lars Heslet
Lars Otto Uttenthal
Original Assignee
Pharmaorigin Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaorigin Aps filed Critical Pharmaorigin Aps
Publication of BRPI0515163A publication Critical patent/BRPI0515163A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

MéTODOS PARA TRATAR HEMOPTISE OU SANGRAMENTO TRAQUEAL, BRÈNQUICO OU ALVEOLAR LOCAL A presente invenção fornece métodos para o tratamento local de hemoptise ou sangramento alveolar, brónquico ou traqueal e/ou redução de efeitos não desejados associados com administração sistêmica de agentes trombóticos a um indivíduo por meio de administração intratraqueal, intrabrónquica ou intraalveolar de um fator de coagulação de sangue ao indivíduo.
BRPI0515163-5A 2004-09-10 2005-09-09 métodos para tratar hemoptise ou sangramento traqueal, brÈnquico ou alveolar local BRPI0515163A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60875904P 2004-09-10 2004-09-10
US62297704P 2004-10-28 2004-10-28
US69396905P 2005-06-24 2005-06-24
PCT/DK2005/000576 WO2006026998A1 (en) 2004-09-10 2005-09-09 Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis

Publications (1)

Publication Number Publication Date
BRPI0515163A true BRPI0515163A (pt) 2008-07-08

Family

ID=35482229

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515163-5A BRPI0515163A (pt) 2004-09-10 2005-09-09 métodos para tratar hemoptise ou sangramento traqueal, brÈnquico ou alveolar local

Country Status (12)

Country Link
US (2) US8431535B2 (pt)
EP (1) EP1791555B1 (pt)
JP (2) JP2008512403A (pt)
KR (1) KR101241434B1 (pt)
AU (1) AU2005282065B2 (pt)
BR (1) BRPI0515163A (pt)
CA (1) CA2579884C (pt)
DK (1) DK1791555T3 (pt)
IL (1) IL181824A (pt)
MX (1) MX2007002903A (pt)
NO (1) NO20071824L (pt)
WO (1) WO2006026998A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002903A (es) 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
WO2007092820A2 (en) 2006-02-03 2007-08-16 Lazarus Effect, Inc. Methods and devices for restoring blood flow within blocked vasculature
DK2004214T3 (da) * 2006-03-16 2013-02-18 Stellaris Pharmaceuticals Aps Lokalbehandling med faktor VII
WO2010102307A1 (en) 2009-03-06 2010-09-10 Lazarus Effect, Inc. Retrieval systems and methods for use thereof
US20120141467A1 (en) * 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
WO2015006299A1 (en) * 2013-07-08 2015-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical formulations of tranexamic acid and their use
US10456560B2 (en) 2015-02-11 2019-10-29 Covidien Lp Expandable tip medical devices and methods
WO2025022005A1 (en) * 2023-07-26 2025-01-30 Le Quellec Sandra Intranasal administration of factor ix polypeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920845A (en) 1971-08-03 1975-11-18 Beecham Group Ltd 2-nitroindan-1,3-dione
US5096916A (en) 1990-05-07 1992-03-17 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
US5427797A (en) 1993-04-06 1995-06-27 Brigham And Women's Hospital Systemic effects of nitric oxide inhalation
US5690910A (en) 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6497877B1 (en) 1997-01-29 2002-12-24 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
GEP20043260B (en) * 1998-03-16 2004-06-25 Nectar Therapeutics Aerosolized Active Agent Delivery and Device for Realization Thereof
ATE308976T1 (de) * 1998-11-10 2005-11-15 Altana Pharma Ag Lungensurfactant zubereitungen enthaltendes behandlungset
DK1282438T3 (da) * 2000-05-10 2005-11-14 Novo Nordisk Healthcare Ag Farmaceutisk sammensætning omfattende en faktor VIIa og en faktor XIII
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
EP1446147A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
DE60327512D1 (de) 2002-02-04 2009-06-18 Salpep Biotechnology Inc Dipeptide und tripeptide mit anti-inflammatorischer wirkung
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
DE60334983D1 (de) * 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
WO2004091487A2 (en) * 2003-04-09 2004-10-28 Wyeth Hemophilia treatment by inhalation of coagulation factors
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US7404957B2 (en) * 2003-08-29 2008-07-29 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
MX2007002903A (es) 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.

Also Published As

Publication number Publication date
JP2012092131A (ja) 2012-05-17
NO20071824L (no) 2007-04-10
JP2008512403A (ja) 2008-04-24
IL181824A (en) 2012-05-31
CA2579884C (en) 2013-12-31
US20070258971A1 (en) 2007-11-08
DK1791555T3 (da) 2013-06-10
US8431535B2 (en) 2013-04-30
IL181824A0 (en) 2007-07-04
AU2005282065B2 (en) 2013-02-07
WO2006026998A1 (en) 2006-03-16
KR20070067127A (ko) 2007-06-27
US7807639B2 (en) 2010-10-05
WO2006026998A8 (en) 2006-05-04
MX2007002903A (es) 2007-07-11
EP1791555A1 (en) 2007-06-06
KR101241434B1 (ko) 2013-03-12
HK1104970A1 (en) 2008-02-01
AU2005282065A1 (en) 2006-03-16
JP5537537B2 (ja) 2014-07-02
CA2579884A1 (en) 2006-03-16
US20070060517A1 (en) 2007-03-15
EP1791555B1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
PH12019501469A1 (en) Compositions and methods for treating biofilms
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
ATE455463T1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
BR112015016466A2 (pt) método para o tratamento de câncer baseado no estado de mutação de k-ras
MX2008010222A (es) Antibioticos nebulizados para terapia de inhalacion.
CR11731A (es) Composiciones y procedimientos para su preparación y uso
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
BRPI0513866A (pt) composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
WO2007143607A3 (en) Method of treating atrophic vaginitis
MX351641B (es) Composicion y aposito para tratamiento de heridas.
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
BRPI0711988A2 (pt) Vidro bioativo, processo para a produção de um vidro bioativo, revestimento, implante, estrutura de suporte porosa bioativa, vidro de estrutura de suporte porosa bioativa, composição e método para a prevenção e/ou o tratamento de danos a um tecido
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
BRPI0811387B8 (pt) kit de administração de um surfactante pulmonar
BR112013021661A2 (pt) objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas
NO20071824L (no) Fremgangsmater til a behandle trakeale, bronkiale eller alveolaere blodninger eller hemoptyse
WO2012051339A3 (en) Methods and compositions for treating respiratory conditions using platelet enriched plasma
SG196863A1 (en) Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
BR112013028786A2 (pt) método e composição de tratamento de sementes
TW200507840A (en) Method of treating multiple myeloma
BRPI0512841A (pt) composições e métodos para o tratamento de infecções patológicas
WO2012174555A3 (en) Composition and method for stabilization and delivery of therapeutic molecules
WO2009098464A3 (en) Use of g-rich oligonucleotides for treating neoplastic diseases

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PHARMAORIGIN APS (DK)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080040797/SP DE 27/06/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.